These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27374158)

  • 41. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease.
    McBride JL; Behrstock SP; Chen EY; Jakel RJ; Siegel I; Svendsen CN; Kordower JH
    J Comp Neurol; 2004 Jul; 475(2):211-9. PubMed ID: 15211462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III).
    Pérez-De La Cruz V; González-Cortés C; Galván-Arzate S; Medina-Campos ON; Pérez-Severiano F; Ali SF; Pedraza-Chaverrí J; Santamaría A
    Neuroscience; 2005; 135(2):463-74. PubMed ID: 16111817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice.
    Mantovani S; Gordon R; Li R; Christie DC; Kumar V; Woodruff TM
    Hum Mol Genet; 2016 May; 25(9):1780-91. PubMed ID: 26908618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The quinolinic acid model of Huntington's disease: locomotor abnormalities.
    Sanberg PR; Calderon SF; Giordano M; Tew JM; Norman AB
    Exp Neurol; 1989 Jul; 105(1):45-53. PubMed ID: 2526022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease.
    Roitberg BZ; Emborg ME; Sramek JG; Palfi S; Kordower JH
    Neurosurgery; 2002 Jan; 50(1):137-45; discussion 145-6. PubMed ID: 11844244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease.
    Sadan O; Shemesh N; Barzilay R; Dadon-Nahum M; Blumenfeld-Katzir T; Assaf Y; Yeshurun M; Djaldetti R; Cohen Y; Melamed E; Offen D
    Exp Neurol; 2012 Apr; 234(2):417-27. PubMed ID: 22285250
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington's disease.
    Stepanova P; Srinivasan V; Lindholm D; Voutilainen MH
    Sci Rep; 2020 Nov; 10(1):19045. PubMed ID: 33154393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of severity of host striatal damage on the morphological development of intrastriatal transplants in a rodent model of Huntington's disease: implications for timing of surgical intervention.
    Watts C; Dunnett SB
    J Neurosurg; 1998 Aug; 89(2):267-74. PubMed ID: 9688122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuroprotective effect of MK-801 against intra-striatal quinolinic acid induced behavioral, oxidative stress and cellular alterations in rats.
    Kalonia H; Kumar P; Nehru B; Kumar A
    Indian J Exp Biol; 2009 Nov; 47(11):880-92. PubMed ID: 20099461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone marrow mesenchymal stem cells can improve the motor function of a Huntington's disease rat model.
    Jiang Y; Lv H; Huang S; Tan H; Zhang Y; Li H
    Neurol Res; 2011 Apr; 33(3):331-7. PubMed ID: 21513650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin.
    Antunes Wilhelm E; Ricardo Jesse C; Folharini Bortolatto C; Wayne Nogueira C
    Eur J Pharmacol; 2013 Feb; 701(1-3):65-72. PubMed ID: 23340221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
    Petersén A; Chase K; Puschban Z; DiFiglia M; Brundin P; Aronin N
    Exp Neurol; 2002 May; 175(1):297-300. PubMed ID: 12009780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus.
    Ayalon L; Doron R; Weiner I; Joel D
    Exp Neurol; 2004 Mar; 186(1):46-58. PubMed ID: 14980809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Xenotransplantation of human adipose derived mesenchymal stem cells in a rodent model of Huntington's disease: motor and non-motor outcomes.
    Hosseini M; Moghadas M; Edalatmanesh MA; Hashemzadeh MR
    Neurol Res; 2015 Apr; 37(4):309-19. PubMed ID: 25376132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.
    Lastres-Becker I; Fezza F; Cebeira M; Bisogno T; Ramos JA; Milone A; Fernández-Ruiz J; Di Marzo V
    Neuroreport; 2001 Jul; 12(10):2125-9. PubMed ID: 11447320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.
    Emerich DF; Winn SR; Hantraye PM; Peschanski M; Chen EY; Chu Y; McDermott P; Baetge EE; Kordower JH
    Nature; 1997 Mar; 386(6623):395-9. PubMed ID: 9121555
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease.
    Ellison DW; Beal MF; Mazurek MF; Malloy JR; Bird ED; Martin JB
    Brain; 1987 Dec; 110 ( Pt 6)():1657-73. PubMed ID: 2892568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntington's Disease Mouse Model.
    Kim D; Jeon J; Cheong E; Kim DJ; Ryu H; Seo H; Kim YK
    Mol Neurobiol; 2016 May; 53(4):2276-86. PubMed ID: 25976370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Energetic dysfunction in quinolinic acid-lesioned rat striatum.
    Bordelon YM; Chesselet MF; Nelson D; Welsh F; Erecińska M
    J Neurochem; 1997 Oct; 69(4):1629-39. PubMed ID: 9326292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.